echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The decline is not the same, the negotiation news is questionable, how to correctly understand the health insurance negotiation?

    The decline is not the same, the negotiation news is questionable, how to correctly understand the health insurance negotiation?

    • Last Update: 2019-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 13, 2019, the national health insurance negotiation will be finished, which means that the 2019 version of the national health insurance catalog will be finally completed It is an important node in the period of building a comprehensive medical insurance system with Chinese characteristics and promoting the high-quality development of China's health insurance Because of the importance of the new medical insurance catalogue, medical insurance and medical insurance negotiation have become the hottest topic in the medical industry this week or even for quite a long time, because it is not only the establishment of a new medical insurance system with Chinese characteristics leading, but also the treatment choice of tens of millions of patients Medical insurance negotiation process and characteristics in 2019 national medical insurance negotiation access process: This on-site negotiation belongs to the fourth stage of medical insurance negotiation access process: the medical insurance party carries out on-site negotiation with the enterprise party, leaves the field to determine the negotiation results, and carries out in several groups The negotiation group randomly selects the negotiation varieties In principle, the competitive products are negotiated in one group, each of which has 30 minutes and two quotation opportunities 1 The negotiation duration is from November 11 to November 13, 2019, which is a huge test for the medical insurance bureau and the negotiation expert group It needs to complete the three-day medical insurance negotiation in a strict and orderly manner 2 The scope of experts involved in the negotiation is large Because there are many kinds of medical insurance negotiation and they are in the implementation node of the new medical insurance system, the level and scope of medical insurance experts are increased In addition to clinical, pharmaceutical and pharmacoeconomics experts, there are also measurement experts and local health care negotiators to promote the scientific demonstration of health care 3 The process is relatively strict From the perspective of organizational process, combined with previous organizational experience, the medical insurance bureau is also relatively strict and confidential about the organizational process of this negotiation Zhu multimedia did not even know that the medical insurance negotiation had started on the same day of the medical insurance negotiation Interpretation of doubtful information this negotiation not only affects the heartstrings of medical practitioners, but also attracts the attention of hundreds of millions of Chinese people In today's era of information explosion, we encounter a lot of information, and also have some questions Let's interpret it from a relatively objective perspective: 1 Some decrease by 5%, some decrease by 50%, and different price reduction scales In this negotiation, there are varieties classification, continuation and new contract varieties First of all, the varieties to be discussed are the ones that have been reduced in the last round of medical insurance negotiation In this negotiation, if you want to enter the new medical insurance catalog, you need to further determine the intended payment price Because these products have experienced a large price drop, the price reduction ratio is relatively low Secondly, the newly signed varieties are of high clinical value and price This time, the price drop will be relatively large Meanwhile, we should also refer to the prices of surrounding countries and the lowest prices in the world As a potential pharmaceutical market, we hope China will get the lowest price treatment 2 Several manufacturers of negotiated varieties of an enterprise indicated at a briefing held by the State Health Insurance Bureau on August 20, 2019 that some of the varieties to be included in the negotiation are patent exclusive varieties with high clinical value but high price or great fund impact It is emphasized that one of the entry barriers for negotiation is exclusive or patent varieties, which means that all negotiation varieties should be exclusive varieties There are several manufacturers of a certain variety in the media report, which is worth considering for readers Even if the health insurance bureau includes non exclusive varieties, there are great challenges in implementation and bidding access We will wait for the official results of the health insurance bureau to be published 3 The number of varieties increased to 150 According to the latest official information, the number of negotiations is 128, with a difference of 22 According to the release of pharmaceutical economic news, in 2017-2018, according to the common name, a total of 128 new drugs will be listed, 10 of which have been approved for negotiation of special anticancer drugs in 2018, 18 of which have added the regular catalogue in 2019, 70 of which will enter this round of negotiation, and 30 of which will not be approved During this period, the official health insurance bureau has not updated the number of negotiated varieties, which may not be true information, or the expert group may temporarily increase the access negotiation of innovative drugs So the question is, what are the admission criteria and selection principles for new varieties? 4 In Tianjin, a company's traditional Chinese medicine injection decreased by about 28% The same media reported the specific price reduction and amount of the company According to the process of signing the confidentiality agreement by the medical insurance bureau, only after the official information is released by the medical insurance bureau, the company can release it to the outside world If it is released in advance, it will be disqualified How this information comes from is worth pondering It is a top priority strategy for pharmaceutical companies to enter the medical insurance reimbursement catalog in the world to set aside the dark clouds and see the sky Selecting good varieties with clinical value is the way for enterprises to enter, and promoting the clinical urgently needed varieties to enter the reimbursement catalog requires multi factor integration 1 To increase the value of access team as the importance of access strategy increases, enterprises need to strengthen the layout of access strategy from the perspective of structure Especially for patent drug enterprises, several patent drugs are about to be listed, so it is very important to study rules, strategies and methods For example, in a multinational pharmaceutical enterprise, the vice president of access strategy has access strategy department, access customer department, central access department, local access department and price team The system structure will support the long-term success of the enterprise access strategy 2 For long-term access preparation of varieties, we need to give priority to important but not urgent events, which also applies at the strategic level If the product access layout can be prioritized in advance, evidence preparation based on the principles of efficacy, safety, economy and applicability can increase the access odds of products We see that too many enterprises have good products, but not enough mining At the end of the adjustment of the medical insurance catalogue, let's review Hu Jinglin's article "promoting the reform and development of medical insurance at a new historical starting point" published in the learning times on July 26, 2019 China's medical insurance industry has achieved considerable development, and has promoted the medical insurance industry in the new era to overcome difficulties, develop innovation, live up to its mission, and build a high quality of loyalty and clean responsibility Quality team, which will push China's medical security to a new height Editor in charge | 37 statement: this point of view only represents the author himself, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.